Sumie Koike

Div Of Experimental Chemotherapy, 3-8-31, Koto Ku
Ariake, 1358550, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Osteocyte-like differentiation of osteosarcoma by inorganic phosphate.

Osteocyte-like differentiation of osteosarcoma by inorganic phosphate.

Journal: Differentiation; research in biological diversity

Published: June 10, 2025

Inhibition of anti-apoptotic Bcl-2 family members promotes synergistic cell death with ER stress inducers by disrupting autophagy in glioblastoma.

Inhibition of anti-apoptotic Bcl-2 family members promotes synergistic cell death with ER stress inducers by disrupting autophagy in glioblastoma.

Journal: Cell death discovery

Published: December 18, 2024

MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.

MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.

Journal: Cancer letters

Published: April 25, 2024

Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma.

Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma.

Journal: Oncogene

Published: November 29, 2023

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.

Journal: Cancer science

Published: May 18, 2022

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.

Journal: NPJ precision oncology

Published: September 04, 2021

Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis.

Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis.

Journal: Oncogene

Published: January 21, 2021

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.

Journal: NPJ precision oncology

Published: October 01, 2020

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.

Journal: Cancer science

Published: November 25, 2019

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.

Journal: Nature communications

Published: September 14, 2018

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

Journal: EBioMedicine

Published: August 08, 2018

Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.

Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.

Journal: Leukemia

Published: January 23, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026